S. Olbricht

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 751 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Jacobus Pfisterer, B. Weber, Rainer Kimmig et al. · JNCI Journal of the National Cancer Institute · 2006 · 209 citations

Medicine, Gynecology, Oncology +16

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Andreas du Bois, B. Weber, Justine Rochon et al. · Journal of Clinical Oncology · 2006 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

Andreas du Bois, H.-J. Lück, Werner Meier et al. · PubMed · 1997 · 58 citations

Medicine, Gynecology, Oncology +12

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

Andreas du Bois, Werner Meier, Hans‐Joachim Lück et al. · Annals of Oncology · 2002 · 54 citations

Medicine, Gynecology, Oncology +13